<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514371</url>
  </required_header>
  <id_info>
    <org_study_id>CA200-003</org_study_id>
    <secondary_id>KAG-302</secondary_id>
    <nct_id>NCT00514371</nct_id>
  </id_info>
  <brief_title>A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma</brief_title>
  <acronym>TIME-2</acronym>
  <official_title>Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma.
      Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a
      fixed dose of bortezomib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2/3 combination study comparing bortezomib plus one of three doses of tanespimycin in
      patients with relapsed-refractory multiple myeloma after failure of at least three prior
      anti-cancer therapy regimens. Prior therapy must include bortezomib and lenalidomide. Primary
      objective is to assess the dose-response relationship of objective response rate (ORR) using
      EBMT/IBMTR criteria of any three dose levels of tanespimycin (KOS-953) in combination with
      bortezomib after four treatment cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>approximately 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate between treatment arms and time-to-event endpoints.</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>tanespimycin and bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bortezomib and tanespimycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bortezomib tanespimycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <description>High dose</description>
    <arm_group_label>tanespimycin and bortezomib</arm_group_label>
    <arm_group_label>bortezomib and tanespimycin</arm_group_label>
    <arm_group_label>bortezomib tanespimycin</arm_group_label>
    <other_name>BMS-722782</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Mid dose, and low dose</description>
    <arm_group_label>tanespimycin and bortezomib</arm_group_label>
    <arm_group_label>bortezomib and tanespimycin</arm_group_label>
    <arm_group_label>bortezomib tanespimycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good performance status

          -  Histologic evidence of multiple myeloma

          -  Have had at least three prior treatment regimens for multiple myeloma that included
             both bortezomib and lenalidomide

          -  No prior treatment with a heat shock 90 inhibitor or an investigational proteasome
             inhibitor

          -  No known infections of HAV, HBV, HCV, or HIV

          -  No chemotherapy, radiation therapy, or immune therapy for three weeks prior to
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <disposition_first_submitted>September 10, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2010</disposition_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Heat Shock Protein 90</keyword>
  <keyword>Hsp90</keyword>
  <keyword>KOS-953</keyword>
  <keyword>17-AAG</keyword>
  <keyword>bortezomib</keyword>
  <keyword>relapsed-refractory</keyword>
  <keyword>tanespimycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

